Diagnosis of the Preterm Patent Ductus Arteriosus: Clinical Signs, Biomarkers, or Ultrasound?

Seminars in Perinatology

Volumn 36, Issue 2, 2012, Pages 114-122

  Evans, Nick ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Ductus arteriosus; Echocardiography; Ibuprofen; Indomethacin; Infant premature; Systemic blood flow

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; INDOMETACIN; TROPONIN T;

ARTERY CONSTRICTION; BLOOD FLOW VELOCITY; BLOOD VESSEL SHUNT; BLOOD VOLUME; CLINICAL FEATURE; DOPPLER ECHOGRAPHY; DUCTUS ARTERIOSUS; HUMAN; IMAGE DISPLAY; LUNG CIRCULATION; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYMPTOMATOLOGY; SYSTEMIC CIRCULATION; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; DUCTUS ARTERIOSUS, PATENT; ECHOCARDIOGRAPHY; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MALE; NATRIURETIC PEPTIDE, BRAIN; PREGNANCY;

EID: 84858242503     PISSN: 01460005     EISSN: 1558075X     Source Type: Journal    
DOI: 10.1053/j.semperi.2011.09.021     Document Type: Review

References (43)

1. Evans N.J., Kluckow M. Early significant ductal shunting and intraventricular haemorrhage in ventilated preterm infants. Arch Dis Child 1996, 75:F183-F186.
2. Kluckow M., Evans N. Ductal shunting, high pulmonary blood flow, and pulmonary haemorrhage. J Pediatr 2000, 137:68-72.
3. Noori S., McCoy M., Friedlich P., et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics 2009, 123:e138-e144.
4. Benitz W.E. Treatment of persistent patent ductus arteriosus in preterm infants: Time to accept the null hypothesis?. J Perinatol 2010, 30:241-252.
5. Bose C.L., Laughon M.M. Patent ductus arteriosus: Lack of evidence for common treatments. Arch Dis Child Fetal Neonatal Ed 2007, 92:F498-F502.
6. Laughon M.M., Simmons M.A., Bose C.L. Patency of the ductus arteriosus in the premature infant: Is it pathologic? Should it be treated?. Curr Opin Pediatr 2004, 16:146-151.
7. de Waal KA, Zonnenberg I: The definition of a hemodynamic significant duct in randomized controlled trials: A systematic literature review. Acta Paediatr (in press).
8. Evans N.J., Archer L.N. Postnatal circulatory adaptation in term and healthy preterm newborns. Arch Dis Child 1990, 65:24-26.
9. Kluckow M., Evans N.J. Low superior vena cava flow and intraventricular haemorrhage in preterm infants. Arch Dis Child 2000, 82:F188-F194.
10. Evans N., Iyer P. Assessment of ductus arteriosus shunting in preterm infants supported by mechanical ventilation: Effect of inter-atrial shunting. J Pediatr 1994, 125:778-785.
11. El Hajjar M., Vaksmann G., Rakza T., et al. Severity of the ductal shunt: A comparison of different markers. Arch Dis Child Fetal Neonatal Ed 2005, 90:F419-F422.
12. Gournay V., Cambonie G., Rozé J.C. Doppler echocardiographic assessment of pulmonary blood flow in healthy newborns. Acta Paediatr 1998, 87:419-423.
13. Groves A.M., Kuschel C.A., Knight D.B., et al. Does retrograde diastolic flow in the descending aorta signify impaired systemic perfusion in preterm infants?. Pediatr Res 2008, 63:89-94.
14. Lemmers P.M., Toet M.C., van Bel F. Impact of patent ductus arteriosus and subsequent therapy with indomethacin on cerebral oxygenation in preterm infants. Pediatrics 2008, 121:142-147.
15. El-Khuffash A., Higgins M., Walsh K., et al. Quantitative assessment of the degree of ductal steal using celiac artery blood flow to left ventricular output ratio in preterm infants. Neonatology 2008, 93:206-212.
16. Evans N., Kluckow M., Simmons M., et al. Which to measure, systemic or organ blood flow?. Middle cerebral artery and superior vena cava flow in preterm infants. Arch Dis Child Fetal Neonatal Ed 2002, 87:F181-F184.
17. Skelton R., Evans N., Smythe J. A blinded comparison of clinical and echocardiographic evaluation of the preterm infant for patent ductus arteriosus. J Paediatr Child Health 1994, 30:406-411.
18. Davis P., Turner-Gomes S., Cunningham K., et al. Precision and accuracy of clinical and radiological signs in premature infants at risk of patent ductus arteriosus. Arch Pediatr Adolesc Med 1995, 149:1136-1141.
19. Van Overmeire B., Van de Broek H., Van Laer P., et al. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr 2001, 138:205-211.
20. Schmidt B., Roberts R.S., Fanaroff A., et al. Indomethacin prophylaxis, patent ductus arteriosus and the risk of bronchopulmonary dysplasia: Further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). J Pediatr 2006, 148:730-734.
21. Fowlie P.W., Davis P.G., McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 2010, 7. CD000174.
22. McNamara P.J., Sehgal A. Towards rational management of the patent ductus arteriosus: The need for disease staging. Arch Dis Child Fetal Neonatal Ed 2007, 92:F424-F427.
23. Kluckow M., Evans N. Ductal shunting, high pulmonary blood flow, and pulmonary haemorrhage. J Pediatr 2000, 137:68-72.
24. Schmidt B., Davis P., Moddemann D., et al. Trial of Indomethacin Prophylaxis in Preterms Investigators: Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. New E J Med 2001, 344:1966-1972.
25. Alfaleh K., Smyth J.A., Roberts R.S., et al. Trial of Indomethacin Prophylaxis in Preterms Investigators: Prevention and 18-month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms. Pediatrics 2008, 121:e233-e238.
26. Evans N., Moorcraft J. Effect of patency of the ductus arteriosus on blood pressure in very preterm infants. Arch Dis Child 1992, 67:1169-1173.
27. Evans N., Iyer P. Change in blood pressure after treatment of patent ductus arteriosus with indomethacin. Arch Dis Child 1993, 68:584-587.
28. El-Khuffash A., Molloy E.J. Are B-type natriuretic peptide (BNP) and N-terminal-pro-BNP useful in neonates?. Arch Dis Child Fetal Neonatal Ed 2007, 92:F320-F324.
29. Puddy V.F., Amirmansour C., Williams A.F., et al. Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci 2002, 103:75-77.
30. Choi B.M., Lee K.H., Eun B.L., et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 2005, 115:e255-e261.
31. Flynn P.A., da Graca R.L., Auld P.A., et al. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. J Pediatr 2005, 147:38-42.
32. Sanjeev S., Pettersen M., Lua J., et al. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol 2005, 25:709-713.
33. El-Khuffash A.F., Amoruso M., Culliton M., et al. N-terminal pro-B-type natriuretic peptide as a marker of ductal haemodynamic significance in preterm infants: A prospective observational study. Arch Dis Child Fetal Neonatal Ed 2007, 92:F421-F422.
34. Cen S., Tacy T., Clyman R. How useful are B-type natriuretic peptide measurements for monitoring changes in patent ductus arteriosus shunt magnitude. J Perinatol 2010, 30:780-785.
35. Czernik C., Lemmer J., Metze B., et al. B-type natriuretic peptide to predict ductus intervention in infants <28 weeks. Pediatr Res 2008, 64:286-290.
36. Attridge J.T., Kaufman D.A., Lim D.S. B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2009, 94:F178-F182.
37. Hsu J.H., Yang S.N., Chen H.L., et al. B-type natriuretic peptide predicts responses to indomethacin in premature neonates with patent ductus arteriosus. J Pediatr 2010, 157:79-84.
38. Hammerman C., Shchors I., Schimmel M.S., et al. N-terminal-pro-B-type natriuretic peptide in premature patent ductus arteriosus: A physiological biomarker but is it a clinical tool?. Pediatr Cardiol 2010, 31:62-65.
39. Bagnoli F., Rossetti A., Casucci M., et al. Amino terminal B-type natriuretic peptide in the therapy of patent ductus arteriosus. Minerva Pediatr 2010, 62:67-70.
40. El-Khuffash A., Barry D., Walsh K., et al. Biochemical markers may identify preterm infants with a patent ductus arteriosus at high risk of death or severe intraventricular haemorrhage. Arch Dis Child Fetal Neonatal Ed 2008, 93:F407-F412.
41. El-Khuffash A.F., Slevin M., McNamara P.J., et al. Troponin T, N-terminal pro natriuretic peptide and a patent ductus arteriosus scoring system predict death before discharge or neurodevelopmental outcome at 2 years in preterm infants. Arch Dis Child Fetal Neonatal Ed 2011, 96:F133-F137.
42. Holmström H., Hall C., Thaulow E. Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus on preterm infants. Acta Paediatr 2001, 90:184-191.
43. El-Khuffash A.F., Molloy E.J. Influence of a patent ductus arteriosus on cardiac troponin T levels in preterm infants. J Pediatr 2008, 153:350-353.